MARKET

CKDXF

CKDXF

Opthea Ltd
OTCPK
0.820
NaN%
Opening 09:30 06/10 EDT
OPEN
--
PREV CLOSE
0.820
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.820
52 WEEK LOW
0.820
MARKET CAP
1.12B
P/E (TTM)
5.59
1D
5D
1M
3M
1Y
5Y
1D
Opthea Schedules Online Market Update for Investors
TipRanks · 1d ago
Opthea relaunches on ASX with rare lung disease push for OPT-302
TipRanks · 06/02 23:24
Opthea calls virtual extraordinary general meeting for July 2026
TipRanks · 06/02 23:23
ASX Flags Delisting Risk for Long-Term Suspended Companies Over Reporting Delays
TipRanks · 04/17 05:18
Opthea Swings to Profit as Net Tangible Assets Turn Positive
TipRanks · 03/01 21:28
Opthea Streamlines Operations, Refocuses on LAM Program as ASX Reinstatement Sought
TipRanks · 01/30 00:58
Opthea Simplifies Capital Structure as 4.45 Million Options and Rights Lapse
TipRanks · 01/15 04:38
Opthea Grants 41 Million Options to Non-Executive Director Katherine Connell
TipRanks · 12/22/2025 22:37
More
About CKDXF
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. It is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. It has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. It is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.

Webull offers Opthea Ltd stock information, including OTCPK: CKDXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CKDXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CKDXF stock methods without spending real money on the virtual paper trading platform.